Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2695]

ESMO GI 2026: Blood test may help identify which colorectal cancer patients with liver metastases are most likely to benefit from chemotherapy after surgery

ESMO GI 2026: Blood test may help identify which colorectal cancer patients with liver metastases are most likely...

Novel biomarker research offers new hope in the fight against colorectal cancer

Novel biomarker research offers new hope in the fight against colorectal cancer

Radioligand therapy significantly prolongs progression-free survival in patients with the most common type of neuroendocrine tumours compared to standard of care

Radioligand therapy significantly prolongs progression-free survival in patients with the most common type of...

Do cancer screening rates differ across sexual orientation and gender identity?

Do cancer screening rates differ across sexual orientation and gender identity?

Uncovering gene-based clues to how disrupted healing in stomach cells increases cancer risk

Uncovering gene-based clues to how disrupted healing in stomach cells increases cancer risk

PLXNC1 – a novel biomarker for consensus molecular subtype 4 in colorectal cancer (CMS4 CRC)

PLXNC1 – a novel biomarker for consensus molecular subtype 4 in colorectal cancer (CMS4 CRC)

Large-scale microbiome study identifies robust colorectal cancer signature

Large-scale microbiome study identifies robust colorectal cancer signature

Scientists uncover a genetic "shield" that lowers the risk of colorectal cancer

Scientists uncover a genetic "shield" that lowers the risk of colorectal cancer

m6A RNA modification in colorectal cancer: Regulatory roles, oncogenic signalling and metabolic pathways

m6A RNA modification in colorectal cancer: Regulatory roles, oncogenic signalling and metabolic pathways

European Commission approves encorafenib in combination with cetuximab and FOLFOX for the first-line treatment of adult patients with BRAF V600E-mutant metastatic colorectal cancer

European Commission approves encorafenib in combination with cetuximab and FOLFOX for the first-line treatment of...

More from ecancer